INLEXZO™
(gemcitabine intravesical system)
INLEXZO™ (gemcitabine intravesical system)
INLEXZO - publications
Daneshmand S, et al. SunRISe-1 Study. TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. J Clin Oncol. 2025 Jul 30:JCO2501651.
Williams S, et al. Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States. J Med Econ. 2026 Dec;29(1):1198-1212.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.